GSK's Endometrial Cancer Treatment Study Shows Combination Potential
By Anthony O. Goriainoff
GSK said results from a study showed the potential for combinations of its Jemperli cancer treatment in patients with primary advanced or recurrent endometrial cancer.
Endometrial cancer is found in the inner lining of the uterus.
The U.K. pharmaceutical giant said Saturday that positive data from the phase 3 study showed Jemperli(dostarlimab)-based regimens could benefit a larger set of patients with endometrial cancer.
The company said dostarlimab plus chemotherapy was the only immuno-oncology combination to show statistically significant and clinically meaningful overall survival rate in the overall population. It added that it saw a 31% reduction in risk of death and a 16.4-month improvement in the median overall survival rate with dostarlimab plus chemotherapy versus chemotherapy alone, and a 37% reduction in risk of disease progression or death.
"Our goal is to continue to identify ways to use dostarlimab alone and in combination with other therapies to help improve outcomes for patients with limited treatment options," the company said.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
March 18, 2024 03:34 ET (07:34 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
What’s Happening In the Markets This Week
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
After Earnings, Is Lyft Stock a Buy, a Sell, or Fairly Valued?
-
8 Stock Picks in the Apparel Industry
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing